| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Polaryx Therapeutics, Inc. Common Stock$2.33
+0.02 (+0.87%)
F 18Pipeline Score Biotech · Clinical
Market Cap
268.91 M
EPS
-0.19
P/E Ratio
-29.93 $
Value Trade
335.21 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
679.00 K
Operating CF
-2.06 M
Total Assets
3.50 M
Total Liabilities
1.01 M
Equity
2.49 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
3.08 M
Monthly Burn
688.00 K
Runway
3.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
15.43 K
52 Week Range
2.20 - 48.91
% held by Insiders
91.81 %
% held by Institutions
4.79 %
Enterprise Value
263.77 M
Total Shares
47.24 M
Short %
8.95 %
Float Shares
10.44 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F18
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 17%
Micro Cap (rank 752 of 905)
Percentile RankPolaryx Therapeutics, Inc. Common Stock has significant pipeline risk (18/100), with 1 assets in development, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX-200 Small molecule | Juvenile Neuronal Ceroid Lipofuscinosis | Phase 3 | NCT04637282 | 50% | - | NOT YET_RECRUITING | 39 | AVERAGE | D (21) | Mar 1, 2026 | ELEVATED_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLYX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Polaryx Therapeutics, Inc. Common Stock (PLYX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PLYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLYX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PLYX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PLYX
May 28, 2026Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics has successfully closed a $10 million private placement equity financing to support the upcoming Phase 2 SOTERIA trial for its lead drug candidate, PLX-200. The trial will evaluate the drug across multiple lysosomal storage disorder indications. With this funding, Polaryx aims to achieve key clinical milestones and extend its operational runway into 2027.
Read more →-PLYX
Apr 23, 2026Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
Polaryx Therapeutics will participate in the NTSAD Annual Family Conference from April 30 to May 3, 2026. The event will allow Polaryx to connect with families and advocates in the rare disease community while sharing updates on its clinical programs. The company is advancing its lead drug candidate, PLX-200, through a Phase 2 trial aimed at treating multiple lysosomal storage disorders.
Read more →-PLYX
Feb 27, 2026Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
Polaryx Therapeutics celebrates Rare Disease Day by reaffirming its commitment to patients with rare pediatric lysosomal storage disorders (LSDs). The company is advancing the SOTERIA trial, which will evaluate the safety and efficacy of its lead candidate, PLX-200, across multiple LSDs. This initiative highlights the urgent need for innovative treatments in this underserved area.
Read more →-PLYX
Feb 17, 2026Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics has selected a contract research organization for its SOTERIA Phase 2 trial, which will evaluate the safety and efficacy of PLX-200 in treating various lysosomal storage disorders. The trial is set to begin in the first half of 2026, following FDA approval. This trial represents a significant step in addressing the needs of patients with rare pediatric disorders.
Read more →-PLYX
Feb 10, 2026Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Polaryx Therapeutics presented encouraging preclinical data for PLX-200, an investigational therapy for Krabbe disease, at the 22nd Annual WORLDSymposium. The findings indicate that gemfibrozil can restore motor functions and increase lifespan in affected mice. The company is preparing to launch the SOTERIA trial to further evaluate PLX-200's efficacy and safety across multiple lysosomal storage disorders.
Read more →-PLYX
Feb 5, 2026Polaryx Therapeutics Welcomes New Members of the Board of Directors
Polaryx Therapeutics has appointed three new members to its Board of Directors, effective January 29, 2026. The new members, Dr. Mitchel Berger, Mr. Francis A. Braun III, and Dr. Charles Ryan, bring extensive expertise in various fields. Their addition comes as Polaryx prepares to advance its lead candidate, PLX-200, into a Phase 2 clinical trial, marking a significant milestone for the company.
Read more →-PLYX
Feb 3, 2026Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Polaryx Therapeutics is set to present late-breaking data on PLX-200 for Krabbe disease at the 22nd Annual WORLDSymposium. This data supports the upcoming SOTERIA trial, a Phase 2 study aimed at evaluating PLX-200's safety and efficacy across several lysosomal storage disorders. The trial is scheduled to begin in the first half of 2026 following FDA approval.
Read more →Competitive Position
How PLYX ranks across every disease it competes inCompetitive Position is a premium feature
See how PLYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial